Naivec Discusses with Multiple Gene Therapy Companies Including 'Moderna' at JP Morgan Healthcare Conference

[Asia Economy Reporter Hyunseok Yoo] Naivek announced on the 18th that following its presentation on peptide-based anticancer drug research conducted with big pharma at the JP Morgan Healthcare Conference, it has been negotiating the provision of materials including the introduction of the ‘NIPEP-TPP’ platform technology, mechanism data, and animal efficacy results to multiple gene medicine development pharmaceutical companies such as Moderna.

At the JP Morgan Conference, Naivek held technology-related discussions in the form of ‘corporate partnering’ meetings with 37 global pharmaceutical companies including Moderna, Daiichi Sankyo, Otsuka, and Merck, following the presentation of peptide anticancer drug research results jointly conducted with global big pharma.

Major global pharmaceutical companies are requesting additional meetings following the JP Morgan Conference, indicating that follow-up discussions from the conference are expected to continue. In particular, the global big pharma companies jointly developing peptide anticancer drugs plan to simultaneously conduct discussions not only on reviewing the data accumulated so far but also on future additional material exchanges.

A Naivek official said, “Naivek received significant attention by presenting its self-developed peptide platform technology and new drug pipeline at the biotech showcase,” adding, “Global pharmaceutical companies showed great interest in anticancer therapeutics and gene therapies based on the ‘drug delivery platform’ capable of delivering drugs to cells and tissues without side effects.”

He continued, “The inflammatory bowel disease treatment and pulmonary fibrosis treatment, which are being developed in oral formulations, have achieved results not only in material transfer but also in receiving proposals for joint research, and follow-up meetings related to this are being coordinated.”

Naivek actively engaged in discussions related to gene drug substances at this year’s conference. Global pharmaceutical companies showed great interest mainly in Naivek’s drug delivery technology that can accurately deliver large molecular gene medicines such as ‘mRNA’ to lesion sites without side effects.

A Naivek official stated, “Since new drugs applying Naivek’s ‘NIPEP-TPP’ platform have excellent functions in effectively delivering drugs to cells and tissues, it was understood at this conference that global pharmaceutical companies developing anticancer and gene therapies have a strong need to incorporate Naivek’s technology into new drug development or upgrading existing drugs,” adding, “Interest in Naivek’s drug delivery technology is so high that not only global pharmaceutical companies but also those pharmaceutical companies that could not hold meetings due to scheduling are requesting follow-up meetings.”